Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

183.10 +8.20 (+4.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,858,665
Open 177.49
Bid (Size) 183.10 (100)
Ask (Size) 183.50 (300)
Prev. Close 174.90
Today's Range 175.45 - 183.51
52wk Range 53.40 - 183.51
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a... 
Via StockStory
News headline image
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire

Performance

YTD
+80.0%
+80.0%
1 Month
+13.3%
+13.3%
3 Month
+41.8%
+41.8%
6 Month
+109.8%
+109.8%
1 Year
+230.5%
+230.5%

More News

Read More
News headline image
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Business Insider Names Guardant Health One of America's Most Innovative Businesses
From Guardant Health, Inc.
Via Business Wire
Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗
Via Chartmill
News headline image
1 Growth Stock to Add to Your Roster and 2 We Turn Down
Via StockStory
News headline image
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Rule Breakers Buy a Stock That's Already "Won" ↗
Via The Motley Fool
Topics Death
News headline image
Guardant Health to Appeal Federal District Court Judgment
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗
Via MarketBeat
News headline image
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
2 Cash-Burning Stocks to Target This Week and 1 We Find Risky
Via StockStory
Topics Energy
News headline image
GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth
Via StockStory
News headline image
Guardant Health Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars
Via StockStory
News headline image
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (GH) Q2 Earnings Report Preview: What To Look For
Via StockStory
News headline image
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Mid-Cap Stocks We’re Skeptical Of
Via StockStory

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 183.10
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 09/17/26 04:00 PM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 18.55B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.